KR20210074290A - 이미다조퀴놀린 화합물 및 이의 용도 - Google Patents

이미다조퀴놀린 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20210074290A
KR20210074290A KR1020217010120A KR20217010120A KR20210074290A KR 20210074290 A KR20210074290 A KR 20210074290A KR 1020217010120 A KR1020217010120 A KR 1020217010120A KR 20217010120 A KR20217010120 A KR 20217010120A KR 20210074290 A KR20210074290 A KR 20210074290A
Authority
KR
South Korea
Prior art keywords
compound
cancer
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217010120A
Other languages
English (en)
Korean (ko)
Inventor
리후 양
Original Assignee
버디 바이오파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버디 바이오파마슈티칼즈, 인크. filed Critical 버디 바이오파마슈티칼즈, 인크.
Publication of KR20210074290A publication Critical patent/KR20210074290A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217010120A 2018-09-07 2019-09-05 이미다조퀴놀린 화합물 및 이의 용도 Ceased KR20210074290A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
KR20210074290A true KR20210074290A (ko) 2021-06-21

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010120A Ceased KR20210074290A (ko) 2018-09-07 2019-09-05 이미다조퀴놀린 화합물 및 이의 용도

Country Status (9)

Country Link
US (1) US20210214354A1 (https=)
EP (2) EP4306523A3 (https=)
JP (1) JP2022501327A (https=)
KR (1) KR20210074290A (https=)
CN (1) CN113164460A (https=)
AU (1) AU2019335366A1 (https=)
CA (1) CA3111786A1 (https=)
ES (1) ES2963112T3 (https=)
WO (1) WO2020051356A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN115916342A (zh) * 2020-07-08 2023-04-04 普渡研究基金会 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
MX377916B (es) * 2014-04-22 2025-03-10 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP3166976B2 (en) * 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
CN115350279A (zh) * 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合

Also Published As

Publication number Publication date
EP3846807B1 (en) 2023-08-02
CN113164460A (zh) 2021-07-23
EP4306523A3 (en) 2024-01-24
EP3846807A4 (en) 2022-05-18
CA3111786A1 (en) 2020-03-12
JP2022501327A (ja) 2022-01-06
US20210214354A1 (en) 2021-07-15
EP3846807A1 (en) 2021-07-14
EP4306523A2 (en) 2024-01-17
ES2963112T3 (es) 2024-03-25
AU2019335366A1 (en) 2021-03-25
WO2020051356A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
KR20210074290A (ko) 이미다조퀴놀린 화합물 및 이의 용도
US10125133B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI652269B (zh) 氮雜吡啶酮化合物及其用途
CN105473592B (zh) 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
IL228317A (en) Pyrimidine derivatives and pharmaceutical preparations containing a signal
US20220251097A1 (en) Molecules and methods related to treatment of uncontrolled cellular proliferation
BR112013029537B1 (pt) derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende
JP2021513986A (ja) キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法
JP4262092B2 (ja) ＬＨ作動活性とＦＳＨ作動活性を合わせ持つチエノ［２，３−ｄ］ピリミジン誘導体
CN111848528B (zh) 一种预防和/或治疗癌症的化合物及其制备方法和应用
WO2019034179A1 (zh) 一种含吲哚环的ido抑制剂及其制备方法
JP2022516922A (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
HK40101420A (en) Imidazoquinoline compounds and uses thereof
US11623918B2 (en) Compounds for the treatment of acute and chronic kidney disease
HK40057163A (en) Imidazoquinoline compounds and uses thereof
HK40057163B (en) Imidazoquinoline compounds and uses thereof
CN112794844B (zh) 酯类化合物及其制备方法和应用、酯类软药
WO2022109066A1 (en) Compounds for the treatment of acute and chronic kidney disease
CN109651362B (zh) 一种苦马豆素衍生物及其制备方法和应用
WO2018133846A1 (zh) 环硫脲类化合物及其用途
US20250353816A1 (en) Quinolines as modulators of polrmt
HK40110742A (zh) 用於靶向递送治疗剂的双环杂环及其配体
JP2022538398A (ja) ウイルス感染症及び更なる疾患の処置用のキナゾリンプロドラッグ
CN116963733A (zh) 作为enpp1抑制剂的咪唑化合物
HK1191949B (en) Quinazoline derivatives for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220722

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241002

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D